NASDAQ:NTLA

Intellia Therapeutics Stock Forecast, Price & News

$74.36

+1.77 (+2.44 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$70.33

Now: $74.36▼

$75.69

50-Day Range

$43.44

MA: $62.75▼

$83.68

52-Week Range

$9.18

Now: $74.36▼

$92.00

Volume1.96 million shs

Average Volume2.00 million shs

Market Capitalization$4.39 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.09

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.34 out of 5 stars

Medical Sector

638th out of 1,923 stocks

Diagnostic Substances Industry

11th out of 32 stocks

2.3 Analyst's Opinion

Consensus Rating
Intellia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 9 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.04, Intellia Therapeutics has a forecasted downside of 34.0% from its current price of $74.36.
Amount of Analyst Coverage
Intellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Intellia Therapeutics has received 329 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Intellia Therapeutics has received 289 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Intellia Therapeutics has received 53.24% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote “Outperform” if you believe NTLA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Intellia Therapeutics does not currently pay a dividend.
Dividend Growth
Intellia Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,876,074.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Intellia Therapeutics is held by insiders.
Percentage Held by Institutions
95.58% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Intellia Therapeutics are expected to decrease in the coming year, from ($2.27) to ($2.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intellia Therapeutics is -32.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intellia Therapeutics is -32.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intellia Therapeutics has a P/B Ratio of 13.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NTLA

Previous Symbol

CUSIPN/A

CIK1652130

Webwww.intelliatx.com

Phone857-285-6200

Employees270

Debt

Debt-to-Equity RatioN/A

Current Ratio7.45

Quick Ratio7.45

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$43.10 million

Price / Sales101.93

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.52 per share

Price / Book13.47

Profitability

EPS (Most Recent Fiscal Year)($2.11)

Net Income$-99,530,000.00

Net Margins-193.01%

Return on Equity-40.14%

Return on Assets-30.11%

Miscellaneous

Outstanding Shares59,081,000

Market Cap$4.39 billion

Next Earnings Date2/25/2021 (Estimated)

OptionableOptionable

$74.36

+1.77 (+2.44 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

How has Intellia Therapeutics' stock been impacted by Coronavirus?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NTLA stock has increased by 484.6% and is now trading at $74.36.
View which stocks have been most impacted by COVID-19.

Is Intellia Therapeutics a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Intellia Therapeutics?

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Intellia Therapeutics.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.47) EPS for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.07. The firm had revenue of $22.22 million for the quarter, compared to analysts' expectations of $14.95 million. Intellia Therapeutics had a negative net margin of 193.01% and a negative trailing twelve-month return on equity of 40.14%. The company's quarterly revenue was up 109.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.49) earnings per share.
View Intellia Therapeutics' earnings history.

What price target have analysts set for NTLA?

14 Wall Street analysts have issued 1 year target prices for Intellia Therapeutics' stock. Their forecasts range from $20.00 to $106.00. On average, they anticipate Intellia Therapeutics' share price to reach $49.04 in the next year. This suggests that the stock has a possible downside of 34.0%.
View analysts' price targets for Intellia Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Intellia Therapeutics' key competitors?

Some companies that are related to Intellia Therapeutics include Quidel (QDEL), Ipsen (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Heska (HSKA), Riot Blockchain (RIOT), Lantheus (LNTH), Meridian Bioscience (VIVO), Celldex Therapeutics (CLDX), Aspira Women's Health (AWH), Quotient (QTNT), Oxford Immunotec Global (OXFD), OncoCyte (OCX), VolitionRx (VNRX) and Nymox Pharmaceutical (NYMX).
View all of NTLA's competitors.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:

Dr. John M. Leonard, Pres, CEO & Director (Age 63, Pay $903.79k)
Mr. Glenn G. Goddard, Exec. VP & CFO (Age 49, Pay $541.84k)
Dr. Andrew D. Schiermeier, Exec. VP & COO (Age 50, Pay $615.98k)
Dr. Laura Sepp-Lorenzino, Exec. VP & Chief Scientific Officer (Age 59, Pay $443.79k)
Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 47)
Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 34)
Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
Dr. Jennifer A. Doudna, Founder & Member of Scientific Advisor Board (Age 56)
Dr. Derrick J. Rossi, Founder & Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.31%), Exchange Traded Concepts LLC (0.01%), XR Securities LLC (0.01%), Buckley Wealth Management LLC (0.01%), Aevitas Wealth Management Inc. (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard, Jose E Rivera and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics.

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Pacer Advisors Inc.. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, John M Leonard, Jose E Rivera, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics or view top insider-selling stocks.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., XR Securities LLC, Buckley Wealth Management LLC, Aevitas Wealth Management Inc., and Sowell Financial Services LLC.
View insider buying and selling activity for Intellia Therapeutics or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $74.36.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $4.39 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 270 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here